Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | GAA | P10253 | 2/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.55 |
| ▸ | ACHE | P22303 | 3/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16511119 | 0.93 | ALDH1A1 (0.73) | ALDH1A1GAASMN1; SMN2CYP2D6HRH3 | |
| SCHEMBL16511225 | 0.92 | ALDH1A1 (0.75) | ALDH1A1GAASMN1; SMN2CYP2D6HRH3 | |
| SCHEMBL12460078 | 0.87 | POLB (0.65) | ALDH1A1GAAKMT2APOLB | |
| SCHEMBL15109546 | 0.87 | HRH3 (0.65) | ALDH1A1GAACYP2D6HRH3ACHE | |
| SCHEMBL14430765 | 0.86 | KMT2A (0.64) | ALDH1A1GAASMN1; SMN2CYP2D6HRH3 | |
| SCHEMBL15109497 | 0.85 | HRH3 (0.63) | ALDH1A1GAASMN1; SMN2HRH3ACHE | |
| SCHEMBL16511120 | 0.84 | GAA (0.81) | ALDH1A1GAASMN1; SMN2CYP2D6CYP3A4 | |
| SCHEMBL5480904 | 0.83 | ALDH1A1 (0.60) | ALDH1A1GAASMN1; SMN2CYP2D6HRH3 | |
| SCHEMBL16511117 | 0.82 | GAA (0.83) | ALDH1A1GAASMN1; SMN2CYP2D6CYP3A4 | |
| SCHEMBL5474719 | 0.81 | SMN1; SMN2 (0.60) | ALDH1A1GAASMN1; SMN2CYP2D6HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070191358-A1 | Novel piperidine derivative for the treatment of depression | ASTRAZENECA AB (SE) | 2007-08-16 | — | — | US | disclosed |
| US-20070191358-A1 | Novel piperidine derivative for the treatment of depression | ASTRAZENECA AB (SE) | 2007-08-16 | — | — | US | disclosed |
| US-20070191358-A1 | Novel piperidine derivative for the treatment of depression | ASTRAZENECA AB (SE) | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191358-A1 | Novel piperidine derivative for the treatment of depression | GRIN2C, TPH2, HTR5A | ALDH1A1 172/4885GAA 4017/4885SMN1; SMN2 3605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.